Penny stocks are shares of smaller or newer companies, often in their early stages of development. These companies, however, have the potential for massive growth if their underlying business succeeds over time.
Most clinical-stage biotech companies at the drug development stage are penny stocks. Two such penny stocks that Wall Street believes are “strong buys” and expects to soar by 306% to 1,183% in 2025 are biotech companies Intellia Therapeutics (NTLA) and Cabaletta Bio (CABA).
